INTRODUCTION: The @entity876 antigen is oncoprotective and when damaged, leads to production of anti- @entity876 . It also predisposes to various @entity5 , including @entity157 ( @entity157 ). Serum anti- @entity876 has been proven to have prognostic and other values in @entity1 with @entity157 . The objectives of this study were to determine the serum pattern, prevalence, diagnostic and prognostic utility of serum anti- @entity876 in Nigerians with @entity157 . METHODS: 41 subjects with @entity157 and 45 apparently-healthy controls were matched for age and sex. Serum anti- @entity876 was determined using @entity876 -autoantibody ELISA kit. RESULTS: The mean age of the @entity1 was 48.9 (+/- 13.8) years, and that of controls was 49.4 (+/- 13.7) years. There was male predominance among the @entity1 , 31 @entity1 (75.6 percent) versus ten @entity1 (24.4 percent), with a male-to-female ratio of 3.1:1. Similar values among controls were 33 @entity1 (73.3 percent) versus 12 @entity1 (26.7 percent), with a male-to-female ratio of 2.75:1. Anti- @entity876 was detectable in the sera of five (12.2 percent) @entity1 and four (8.9 percent) of controls (p-value is greater than 0.05). All the @entity1 with positive sera were males, while one of the controls was a female. Three (60 percent) of the positive @entity1 were in the age range 40-49 years, while in the control group, they were in the age range 50-59 years. CONCLUSION: There is a low prevalence of serum anti- @entity876 in our study population, and this is commoner in @entity1 . It is also present in the control group and therefore may not be useful as a diagnostic tool in this study population.

Evaluation of the pattern and prognostic implications of anti- XXXX in @entity157 .

@entity876 :: ('7157', 'Gene') :: ['p53'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers']
@entity876 :: (7157,Gene) :: ['p53']
